土茯苓单味辅助治疗湿热蕴结型急性痛风性关节炎临床疗效

Clinical effect of single Glabrous Greenbrier Rhizome adjuvant in the treatment of acute gouty arthritis with damp-heat syndrome

目的观察土茯苓单味辅助治疗湿热蕴结型急性痛风性关节炎的临床效果。方法选择2017年1月-2018年9月陆军军医大学第一附属医院收治的湿热蕴结型急性痛风性关节炎患者116例,按奇偶分类法随机分为中药组(n=58)与常规组(n=58)。常规组患者给予双氯芬酸钠米索前列醇片治疗,中药组在常规组治疗的基础上加用单味土茯苓汤治疗。比较2组患者治疗前后关节局部症状评分、空腹血尿酸水平及不良反应。结果治疗后,2组患者关节局部症状评分均降低(P<0.05),且中药组低于常规组(P<0.01);治疗后,2组患者空腹血尿酸水平均降低(P<0.05),且中药组低于常规组(P<0.01);中药组患者不良反应发生率为5.17%,低于常规组的17.24%(χ^2=4.245,P=0.039)。结论土茯苓单味辅助治疗湿热蕴结型急性痛风性关节炎效果较好,具有推广价值。

Objective To observe the clinical effect of single Glabrous Greenbrier Rhizome adjuvant in the treatment of acute gouty arthritis with damp-heat syndrome.Methods 116 patients with acute gouty arthritis with damp-heat syndrome selected from the First Hospital Affiliated to Army Medical University from September 2017 to September 2018,randomly divided into traditional Chinese medicine group(n=58)and conventional group(n=58)according to parity classification.The patients in the conventional group was treated with diclofenac sodium and misoprostol tablets,and the Chinese medicine group was treated with single Glabrous Greenbrier Rhizome decoction on the basis of the conventional group.The local symptom scores of joints,fasting blood uric acid level and adverse reactions before and after treatment were compared in the two groups.Results After treatment,the local symptom scores of joints of the two groups of patients decreased(P<0.05),and the Chinese medicine group was lower than the conventional group(P<0.01);After treatment,the fasting blood uric acid level of the two groups of patients decreased(P<0.05),and the Chinese medicine group was lower than the conventional group(P<0.01);The incidence of adverse reactions in the Chinese medicine group was 5.17%,which was lower than 17.24%of the conventional group(χ^2=4.245,P=0.039).Conclusion Single Glabrous Greenbrier Rhizome adjuvant in the treatment of acute gouty arthritis with damp-heat syndrome has a good effect,and this method has promotion value.